van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM (2017) Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. https://doi.org/10.1038/bcj.2017.85

Article  PubMed  PubMed Central  Google Scholar 

Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16:888–897. https://doi.org/10.1158/1078-0432.CCR-09-2069

Article  PubMed  CAS  Google Scholar 

Goyal A, Patel S, Goyal K, Morgan EA, Foreman RK (2019) Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J Cutan Pathol 46:823–829. https://doi.org/10.1111/cup.13545

Article  PubMed  Google Scholar 

Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP (2016) Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol 43:1161–1166. https://doi.org/10.1111/cup.12797

Article  PubMed  Google Scholar 

Arai H, Furuichi S, Nakamura Y, Nakamura Y, Ichikawa M, Mitani K (2016) ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. Rinsho Ketsueki 57:634–637. Japanese. https://doi.org/10.11406/rinketsu.57.634

WHO Classification of Tumours Editorial Board (2022) Hematolymphoid tumors [Internet; beta version ahead of print (in progress)]. Lyon (France): International Agency for Research on Cancer. (WHO classification of tumors series, 5th ed.). https://tumourclassification.iarc.who.int. Accessed 18 June 2023

Feldman AL, Oishi N, Ketterling RP, Ansell SM, Shi M, Dasari S (2022) Immunohistochemical approach to genetic subtyping of anaplastic large cell lymphoma. Am J Surg Pathol 46:1490–1499. https://doi.org/10.1097/PAS.0000000000001941

Article  PubMed  PubMed Central  Google Scholar 

Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473–1480. https://doi.org/10.1182/blood-2014-04-571091

Article  PubMed  PubMed Central  CAS  Google Scholar 

Horwitz S, O’Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T (2022) The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33:288–298. https://doi.org/10.1016/j.annonc.2021.12.002

Article  PubMed  CAS  Google Scholar 

Maeshima AM, Taniguchi H, Fujino T, Saito Y, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K (2020) Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. Ann Hematol 99:2141–2148. https://doi.org/10.1007/s00277-019-03853-1

Article  PubMed  CAS  Google Scholar 

Miyoshi H, Arakawa F, Sato K, Kimura Y, Kiyasu J, Takeuchi M, Yoshida M, Ichikawa A, Ishibashi Y, Nakamura Y, Nakashima S, Niino D, Sugita Y, Ohshima K (2012) Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment. Cancer Sci 103:1567–1573. https://doi.org/10.1111/j.1349-7006.2012.02307.x

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113:4885–4893. https://doi.org/10.1182/blood-2008-08-175208

Article  PubMed  CAS  Google Scholar 

Sugimoto T, TomitaA HJ, Shimada K, Kiyoi H, Kinoshita T, Naoe T (2009) Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 390:48–53. https://doi.org/10.1016/j.bbrc.2009.09.059

Article  PubMed  CAS  Google Scholar 

Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, Thomas SH, Forman SJ, Kane SE (2015) CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther 14:1376–1384. https://doi.org/10.1158/1535-7163.MCT-15-0036

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maeshima AM, Taniguchi H, Fukuhara S, Norikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobina K, Tsuda H (2013) Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Am J Surg Pathol 37:563–570. https://doi.org/10.1097/PAS.0b013e3182759008

Article  PubMed  Google Scholar 

Makita S, Maeshima AM, Taniguchi H, Kitahara H, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Kobayashi Y, Tobinai K (2016) Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma. Int J Hematol 104:396–399. https://doi.org/10.1007/s12185-016-2018-y

Article  PubMed  CAS  Google Scholar 

Marques-Piubelli ML, Kim DH, Medeiros LJ, Lu W, Khan K, Gomez-Bolanos LI, Rodriguez S, Parra ER, Ok CY, Aradhya A, Solis LM, Nieto YL, Steiner R, Ahmed S, Vega F (2023) CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology 83:143–148. https://doi.org/10.1111/his.14910

Article  PubMed  Google Scholar